
Court Leaves States to Decide on Trans Treatments for Minors
Since 2021, states have split nearly evenly over whether to prohibit or protect access to puberty blockers and hormone therapies for transgender adolescents. Like the Supreme Court's 2022 decision in Dobbs v. Jackson Women's Health Organization, which made access to abortion dependent on which state a person lives in, the decision this week is likely to deepen the state-by-state divide over medical care for young trans people.
Just as some states enacted more restrictive abortion limits after Dobbs, states that have enacted partial or total bans on transition treatment for minors may be emboldened to expand on them or enforce them more aggressively, said Brad Sears, a senior scholar at the Williams Institute, a U.C.L.A. program that studies L.G.B.T.Q. legal issues. And just as some states have enshrined reproductive rights in their constitutions, states that have enacted legal shields for health care workers who provide gender-transition treatments may push for more comprehensive protections.
'The reactions to the Dobbs decision are an appropriate place to go to see what might happen next,' Mr. Sears said. 'If you overlay a map of the states with bans and the states with shield laws, you're pretty much seeing two countries.'
In some ways, medical providers and families of trans adolescents have already adjusted to a fragmented legal landscape as states passed disparate laws in the absence of an overarching legal decision. In contrast to Dobbs, the decision to uphold a Tennessee law banning treatments for transgender youths did not overturn a constitutional right that had been recognized for decades. In all but two states that have enacted bans, courts have allowed the limits to go into effect even as legal challenges proceeded.
That has meant that some of an estimated 100,000 families with transgender children living in states with bans have moved to states that permit treatment. Other families have made arrangements to travel out of state for treatments. Many patients in Southern states where treatments are banned, for instance, travel to Virginia, while those in the Midwest often go to Minnesota.
Want all of The Times? Subscribe.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
a minute ago
- Yahoo
GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic
-- GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review application for gepotidacin, an oral antibiotic aimed at treating sexually transmitted uncomplicated gonorrhoea. The drugmaker's shares climbed 1% in London on the news. The company is looking to new infectious disease products, including its recently launched respiratory syncytial virus vaccine, to offset expected revenue declines from top-selling medicines and looming patent expirations in its HIV portfolio. Gepotidacin is already approved in the U.S. under the brand name Blujepa for treating a common urinary tract infection in women and adolescent girls. The FDA is expected to decide in December on its use for uncomplicated urogenital gonorrhoea, which could offer patients an oral alternative to existing injectable treatments. Separately, GSK and Germany's CureVac last week resolved a long-running patent dispute with Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) over mRNA vaccine technology used during the COVID-19 pandemic. The settlement follows BioNTech's June agreement to acquire CureVac in an all-stock deal worth $1.25 billion to advance work on mRNA-based cancer therapies. Under the settlement, CureVac and GSK will receive $740 million and single-digit percentage royalties on future U.S. sales of COVID-19 vaccines, CureVac said. GSK's share amounts to $370 million, including $50 million to adjust terms from a 2024 licence agreement that expanded their pandemic-era partnership. If BioNTech's takeover of CureVac is completed, related mRNA litigation outside the U.S. will also be resolved, with GSK receiving an additional $130 million and royalties extended to non-U.S. sales. CureVac said the acquisition remains on track under the agreed terms. GSK said it still has separate patent cases against Pfizer and BioNTech in the U.S. and Europe, which are unaffected by this settlement. Related articles GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic USPS blocks major vape distributor over unregulated product shipments - Reuters Exclusive: Opendoor CEO Wheeler breaks silence, EMJ's Eric Jackson calls for more Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Ben Askren Reveals What Awakened in Him After His 45-Day Coma
Ben Askren Reveals What Awakened in Him After His 45-Day Coma originally appeared on Athlon Sports. Ben Askren opens up after dying four times and waking from a 45-day coma The combat sports world has seen its share of comebacks—but none like this. After a 45-day coma, multiple cardiac arrests, and a life-saving double lung transplant, former UFC star Ben Askren has returned home and broken his silence. The 41-year-old revealed that he flatlined not once, but four times while battling a severe staph infection that left him on life support. What followed wasn't just a physical transformation—it was a spiritual one. In a clip shared by Happy Punch, Askren confirmed that he woke up from his coma with a newfound faith after 15 years of denying Christianity. 'I woke up and I started as a Christian. I hadn't gone with my wife to church for 15 years—that was part of the deal. I said, 'I'm not a Christian, but I will support you.' When I woke up, I knew I had to do it.' he revealed in an emotional video posted to social media. He's now focused on recovery after spending 59 days in the hospital—but the journey has taken another turn. Askren is currently back in the hospital following concerns over a suspected chest tube infection, as reported by Yahoo Sports. He's receiving antibiotics and undergoing additional imaging to monitor the situation. While it's a discouraging setback, Askren has remained positive, acknowledging that healing isn't always a straight line and expressing hope to be back home soon. Askren's battle isn't over—but his second act is just beginning. With each step forward and every obstacle faced, he continues to show the same resilience that once made him a champion in the cage—only now, the fight is for something far greater than a title. This story was originally reported by Athlon Sports on Aug 7, 2025, where it first appeared.
Yahoo
an hour ago
- Yahoo
12 Bath Products For Babies and Toddlers
Splish splash, it's time for baby's bath. Rubber duckies, bubble bath soap, and cozy towels are all classic baby bath time staples. Now, in addition to those childhood favorites, there are more products on the market than ever before for parents to choose from. Between shampoo and wash, toys and aftercare, the drugstore aisle can get a little overwhelming. Don't fret. Instead, here are some suggestions for suds (and other helpful stuff) that make for a more blissful bath time. Bath Support Assuming your bathtub is too big for a little baby (which is more than likely), here's a tool to help them lay comfortably in the tub and free your hands for soaping, shampooing and rinsing. Wash Time to get fresh and clean, without worrying about skin sensitivities. Shampoo & Wash Save time (and space) with these 2-in-1 bath products. Bath Toys Add some entertainment to bath time with toys. Who said getting clean isn't fun? Hair Brush Even babies have flyaways and messy hair. Thankfully, there are tools to gently fix baby's bedhead. Booger Help Stuffed noses happen, but nasal assistance is on the way! Baby Oil Although baby oil can be used to moisturize on its own, it can also be added to bath time. Lotion Dermatologist-tested lotion for the whole body (and the whole family) is a win. Apply after bathing and as needed. Towels When the bath ends, it's time to dry off with absorbent towels that are soft to the touch. Toothbrush It's never too early to start a good oral hygiene routine.